Alexander H Enk
Overview
Explore the profile of Alexander H Enk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
177
Citations
2955
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hogrefe K, Winkler J, Enk A
Dermatol Ther (Heidelb)
. 2025 Jan;
15(1):237-244.
PMID: 39751746
Pemphigus vulgaris is a severe and often therapy-resistant bullous autoimmune disease. Standard therapy with steroids often administered together with another immunosuppressant does not respond in all patients or may not...
2.
Reschke R, Sullivan R, Lipson E, Enk A, Gajewski T, Hassel J
Trends Immunol
. 2024 Dec;
46(1):61-73.
PMID: 39732529
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are frequently associated with immune-related adverse events (irAEs). This article offers a novel synthesis of findings from both preclinical and clinical...
3.
Reschke R, Enk A, Hassel J
Am J Clin Dermatol
. 2024 Dec;
26(2):213-223.
PMID: 39707058
Melanoma, a highly aggressive form of skin cancer, has seen significant advancements in treatment through the introduction of immunotherapy. However, the variability in patient responses underscores the need for reliable...
4.
Reschke R, Richter J, Enk A, Hassel J
JAMA Dermatol
. 2024 Nov;
161(1):104-105.
PMID: 39504038
No abstract available.
5.
Vollmer A, Wiedenmayer N, Winkler J, Enk A
Case Rep Dermatol
. 2024 Oct;
16(1):210-215.
PMID: 39473559
Introduction: We provide a case report on a patient with scleromyxedema treated with high-dose intravenous immunoglobulins (IVIgs) who reported less fatigue and fewer headaches after transitioning to Yimmugo, a novel...
6.
Mousa A, Enk A, Hassel J, Reschke R
Cells
. 2024 Oct;
13(19.
PMID: 39404378
Non-melanoma skin cancer (NMSC) is primarily categorized into basal cell carcinoma (BCC), the most prevalent form of skin cancer, and cutaneous squamous cell carcinoma (cSCC), the second most common type....
7.
Wiedenmayer N, Hogrefe K, Mihalceanu S, Winkler J, Enk A
J Dermatol
. 2024 Sep;
51(12):1665-1668.
PMID: 39349366
Pemphigus vulgaris (PV) is a severe autoimmune bullous dermatosis that is characterized by autoantibodies against epidermal adhesion proteins causing painful mucosal and skin blistering. Standard treatments for PV include corticosteroids,...
8.
Reschke R, Enk A, Hassel J
Pharmaceutics
. 2024 Aug;
16(8).
PMID: 39204391
Uveal melanoma represents a rare and aggressive subtype of melanoma with limited treatment options and poor prognosis, especially in the metastatic setting. Tebentafusp, a bispecific fusion protein, offers a promising...
9.
Reschke R, Enk A, Hassel J
Int J Mol Sci
. 2024 Jun;
25(12).
PMID: 38928238
Chemokines and cytokines represent an emerging field of immunotherapy research. They are responsible for the crosstalk and chemoattraction of immune cells and tumor cells. For instance, CXCL9/10/11 chemoattract effector CD8...
10.
Wiedenmayer N, Vollmer A, Winkler J, Enk A
Dermatol Ther (Heidelb)
. 2024 Jun;
14(7):1969-1974.
PMID: 38865042
Pemphigus vulgaris (PV) is a rare autoimmune bullous dermatosis (AIBD) characterized by painful blistering of the skin and mucosa caused by autoantibodies that lead to loss of adhesion in the...